Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Gilbert

Showing results (21-30 of 173) with videos related to

Pageof 18
Sort By:
Clinical Science (London, England : 1979)|January 10, 2003
Urotensin II: a new player in vascular and myocardial disease?Henry Krum, Richard E Gilbert
Diabetes, Obesity & Metabolism|May 4, 2019
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trialsRichard E Gilbert, Kevin E Thorpe
The Lancet. Diabetes & Endocrinology|November 23, 2015
Understanding EMPA-REG OUTCOMERichard E Gilbert, Kim A Connelly
Cardiovascular Diabetology|January 13, 2019
Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausibleRichard E Gilbert, Kim A Connelly
The New England Journal of Medicine|April 12, 2008
Activated protein C and diabetic nephropathyRichard E Gilbert, Philip A Marsden
Journal of the American College of Cardiology|February 28, 2009
Novel risk factors for heart failure when the whole may be greater than the sum of its partsJ Malcolm O Arnold, Richard E Gilbert
Canadian Journal of Diabetes|April 14, 2018
Treatment of Diabetes in People With Heart Failure, Kim A Connelly, Richard E Gilbert, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|April 16, 2004
Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal diseaseRichard E Gilbert, Stephen A Douglas, Henry Krum
Kidney International|October 22, 2004
Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetesLesley Wassef, Darren J Kelly, Richard E Gilbert
Seminars in Nephrology|October 16, 2012
Cell therapy for diabetic nephropathy: is the future, now?Richard E Gilbert, Yanling Zhang, Darren A Yuen
Pageof 18

Showing results (21-30 of 173) with videos related to

Sort By:
Pageof 18
Clinical Science (London, England : 1979)|January 10, 2003
Urotensin II: a new player in vascular and myocardial disease?Henry Krum, Richard E Gilbert
Diabetes, Obesity & Metabolism|May 4, 2019
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trialsRichard E Gilbert, Kevin E Thorpe
The Lancet. Diabetes & Endocrinology|November 23, 2015
Understanding EMPA-REG OUTCOMERichard E Gilbert, Kim A Connelly
Cardiovascular Diabetology|January 13, 2019
Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausibleRichard E Gilbert, Kim A Connelly
The New England Journal of Medicine|April 12, 2008
Activated protein C and diabetic nephropathyRichard E Gilbert, Philip A Marsden
Journal of the American College of Cardiology|February 28, 2009
Novel risk factors for heart failure when the whole may be greater than the sum of its partsJ Malcolm O Arnold, Richard E Gilbert
Canadian Journal of Diabetes|April 14, 2018
Treatment of Diabetes in People With Heart Failure, Kim A Connelly, Richard E Gilbert, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|April 16, 2004
Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal diseaseRichard E Gilbert, Stephen A Douglas, Henry Krum
Kidney International|October 22, 2004
Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetesLesley Wassef, Darren J Kelly, Richard E Gilbert
Seminars in Nephrology|October 16, 2012
Cell therapy for diabetic nephropathy: is the future, now?Richard E Gilbert, Yanling Zhang, Darren A Yuen
Pageof 18